| Sow Kobayashi, MD | |
|
1415 Ross Ave, El Centro, CA 92243-4306 | |
| (760) 339-7100 | |
| Not Available |
| Full Name | Sow Kobayashi |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 13 Years |
| Location | 1415 Ross Ave, El Centro, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205194578 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | M-1887 (Guam) | Secondary |
| 207P00000X | Emergency Medicine | A122861 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sharp Chula Vista Medical Center | Chula vista, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cep America - California | 6103739131 | 954 |
News Archive
Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.
Researchers from Brigham and Women's Hospital (BWH) are the first to discover that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. This finding also brings the medical community a step closer toward a new treatment for the debilitating neurological disease that affects approximately 30,000 Americans.
The Senate Appropriations Committee unanimously passed a bill Tuesday that would make long-term health care more affordable for middle-class families. Rep. Steve Farley, D-Tucson, sponsored House Bill 2713, which would allow Arizonans to set aside money in a tax-deductible savings account to pay for long-term health-care expenses. It would also create tax deductions for long-term health insurance premiums.
Trevena Inc., the leader in G-protein coupled receptor biased ligand drug discovery, today announced the initiation of a Phase 2a clinical trial with its lead program, TRV120027, a beta-arrestin biased angiotensin II type 1 receptor ligand, the first biased ligand designed to treat patients with acute heart failure.
› Verified 5 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.
Researchers from Brigham and Women's Hospital (BWH) are the first to discover that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. This finding also brings the medical community a step closer toward a new treatment for the debilitating neurological disease that affects approximately 30,000 Americans.
The Senate Appropriations Committee unanimously passed a bill Tuesday that would make long-term health care more affordable for middle-class families. Rep. Steve Farley, D-Tucson, sponsored House Bill 2713, which would allow Arizonans to set aside money in a tax-deductible savings account to pay for long-term health-care expenses. It would also create tax deductions for long-term health insurance premiums.
Trevena Inc., the leader in G-protein coupled receptor biased ligand drug discovery, today announced the initiation of a Phase 2a clinical trial with its lead program, TRV120027, a beta-arrestin biased angiotensin II type 1 receptor ligand, the first biased ligand designed to treat patients with acute heart failure.
› Verified 5 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780870899 PECOS PAC ID: 6406760131 Enrollment ID: O20031117000940 |
News Archive
Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.
Researchers from Brigham and Women's Hospital (BWH) are the first to discover that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. This finding also brings the medical community a step closer toward a new treatment for the debilitating neurological disease that affects approximately 30,000 Americans.
The Senate Appropriations Committee unanimously passed a bill Tuesday that would make long-term health care more affordable for middle-class families. Rep. Steve Farley, D-Tucson, sponsored House Bill 2713, which would allow Arizonans to set aside money in a tax-deductible savings account to pay for long-term health-care expenses. It would also create tax deductions for long-term health insurance premiums.
Trevena Inc., the leader in G-protein coupled receptor biased ligand drug discovery, today announced the initiation of a Phase 2a clinical trial with its lead program, TRV120027, a beta-arrestin biased angiotensin II type 1 receptor ligand, the first biased ligand designed to treat patients with acute heart failure.
› Verified 5 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578672184 PECOS PAC ID: 3577476761 Enrollment ID: O20031211000464 |
News Archive
Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.
Researchers from Brigham and Women's Hospital (BWH) are the first to discover that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. This finding also brings the medical community a step closer toward a new treatment for the debilitating neurological disease that affects approximately 30,000 Americans.
The Senate Appropriations Committee unanimously passed a bill Tuesday that would make long-term health care more affordable for middle-class families. Rep. Steve Farley, D-Tucson, sponsored House Bill 2713, which would allow Arizonans to set aside money in a tax-deductible savings account to pay for long-term health-care expenses. It would also create tax deductions for long-term health insurance premiums.
Trevena Inc., the leader in G-protein coupled receptor biased ligand drug discovery, today announced the initiation of a Phase 2a clinical trial with its lead program, TRV120027, a beta-arrestin biased angiotensin II type 1 receptor ligand, the first biased ligand designed to treat patients with acute heart failure.
› Verified 5 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548667843 PECOS PAC ID: 6103739131 Enrollment ID: O20040121000458 |
News Archive
Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.
Researchers from Brigham and Women's Hospital (BWH) are the first to discover that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. This finding also brings the medical community a step closer toward a new treatment for the debilitating neurological disease that affects approximately 30,000 Americans.
The Senate Appropriations Committee unanimously passed a bill Tuesday that would make long-term health care more affordable for middle-class families. Rep. Steve Farley, D-Tucson, sponsored House Bill 2713, which would allow Arizonans to set aside money in a tax-deductible savings account to pay for long-term health-care expenses. It would also create tax deductions for long-term health insurance premiums.
Trevena Inc., the leader in G-protein coupled receptor biased ligand drug discovery, today announced the initiation of a Phase 2a clinical trial with its lead program, TRV120027, a beta-arrestin biased angiotensin II type 1 receptor ligand, the first biased ligand designed to treat patients with acute heart failure.
› Verified 5 days ago
| Entity Name | Alvarado Emergency Medical Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285811992 PECOS PAC ID: 0042396251 Enrollment ID: O20080328000280 |
News Archive
Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.
Researchers from Brigham and Women's Hospital (BWH) are the first to discover that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. This finding also brings the medical community a step closer toward a new treatment for the debilitating neurological disease that affects approximately 30,000 Americans.
The Senate Appropriations Committee unanimously passed a bill Tuesday that would make long-term health care more affordable for middle-class families. Rep. Steve Farley, D-Tucson, sponsored House Bill 2713, which would allow Arizonans to set aside money in a tax-deductible savings account to pay for long-term health-care expenses. It would also create tax deductions for long-term health insurance premiums.
Trevena Inc., the leader in G-protein coupled receptor biased ligand drug discovery, today announced the initiation of a Phase 2a clinical trial with its lead program, TRV120027, a beta-arrestin biased angiotensin II type 1 receptor ligand, the first biased ligand designed to treat patients with acute heart failure.
› Verified 5 days ago
| Entity Name | Corona Regional Emergency Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134629298 PECOS PAC ID: 9133481484 Enrollment ID: O20180326001396 |
News Archive
Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.
Researchers from Brigham and Women's Hospital (BWH) are the first to discover that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. This finding also brings the medical community a step closer toward a new treatment for the debilitating neurological disease that affects approximately 30,000 Americans.
The Senate Appropriations Committee unanimously passed a bill Tuesday that would make long-term health care more affordable for middle-class families. Rep. Steve Farley, D-Tucson, sponsored House Bill 2713, which would allow Arizonans to set aside money in a tax-deductible savings account to pay for long-term health-care expenses. It would also create tax deductions for long-term health insurance premiums.
Trevena Inc., the leader in G-protein coupled receptor biased ligand drug discovery, today announced the initiation of a Phase 2a clinical trial with its lead program, TRV120027, a beta-arrestin biased angiotensin II type 1 receptor ligand, the first biased ligand designed to treat patients with acute heart failure.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sow Kobayashi, MD Po Box 232410, San Diego, CA 92193-2410 Ph: () - | Sow Kobayashi, MD 1415 Ross Ave, El Centro, CA 92243-4306 Ph: (760) 339-7100 |
News Archive
Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.
Researchers from Brigham and Women's Hospital (BWH) are the first to discover that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. This finding also brings the medical community a step closer toward a new treatment for the debilitating neurological disease that affects approximately 30,000 Americans.
The Senate Appropriations Committee unanimously passed a bill Tuesday that would make long-term health care more affordable for middle-class families. Rep. Steve Farley, D-Tucson, sponsored House Bill 2713, which would allow Arizonans to set aside money in a tax-deductible savings account to pay for long-term health-care expenses. It would also create tax deductions for long-term health insurance premiums.
Trevena Inc., the leader in G-protein coupled receptor biased ligand drug discovery, today announced the initiation of a Phase 2a clinical trial with its lead program, TRV120027, a beta-arrestin biased angiotensin II type 1 receptor ligand, the first biased ligand designed to treat patients with acute heart failure.
› Verified 5 days ago
Charles H Norton, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1415 Ross Ave, El Centro, CA 99243 Phone: 760-339-7254 | |
Victor Lin, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1415 Ross Ave, El Centro, CA 92243 Phone: 760-339-7100 | |
Albert D Johnson, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1415 Ross Ave, El Centro, CA 92243 Phone: 760-339-7254 | |
George J Rodriguez, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1415 Ross Ave, El Centro, CA 99243 Phone: 760-339-7254 | |
Robert W Ruiz, P.A. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1415 Ross Avenue, El Centro, CA 99243 Phone: 619-660-1168 | |
Ralph S Peiris, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1415 Ross Avenue, El Centro, CA 99243 Phone: 760-339-7254 |